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Summary 
D  factor, also known as leukemia inhibitory factor, is a pleiotropic cytokine whose role during 
acute injury and inflammation is not known. Intraperitoneal administration of Escherichia coli 
endotoxin induced D factor gene expression in mice, and passive immunization against D factor 
protected them from the lethal effects of endotoxin and blocked endotoxin-induced increases 
in serum levels of interleukin 1 and 6. Peak levels of tumor necrosis factor and interferon 3~ were 
not affected. These results indicate that D factor is an essential early mediator of the inflammatory 
cytokine response and therefore may be important in the pathogenesis of the many inflammatory 
conditions,  such as sepsis,  arthritis,  allograft rejection, and cancer immunotherapy. 
D 
ifferentiation-inducing factor/leukemia inhibitory factor 
(D factor/LIF) is a recently identified cytokine with 
an impressive array of seemingly unrelated activities (1, 2). 
First described because of its ability to induce differentiation 
of murine M1 leukemia cells (3, 4), D  factor has been in- 
dependently identified under several synonyms: leukemia in- 
hibitory  factor  (LIF),  differentiation-inhibiting  factor  (D 
factor), osteoclast-activating factor (OAF), human interleukin 
for DA-1 cells (HILDA), cholinergic neuronal differentiation 
factor (CNDF),  hepatocyte-stimulating factor (HSF-II and 
III),  and  melanocyte-derived lipoprotein  lipase  inhibitor 
(MLPLI), and is now recognized to have pleiotropic actions 
in regulating metabolism, growth, and differentiation. Al- 
though diverse effects of D factor have been identified in vitro 
(5-11) and in vivo (12-16), little is known about its role during 
acute and chronic inflammation. It can be produced by a va- 
riety of cells, including fibroblasts (3, 17), monocytes, mac- 
rophages (18), and T lymphocytes (19), and its synthesis can 
be induced by TNF, IL-1, and endotoxin (LPS) (17, 20, 21). 
In addition, elevated levels of D  factor have been identified 
in the body fluids of patients with a variety of acute and chronic 
inflammatory conditions, such as septic shock, rheumatoid 
arthritis,  renal aUograft rejection, and cancer (20,  22,  23). 
These findings suggest that D  factor participates in the 
regulation of immune system function and is a mediator of 
inflammation. However, pretreatment of rodents with D factor 
appears to have antiinflammatory consequences, protecting 
them against a lethal dose of LPS (24) and enhancing host 
resistance against radiation injury (25) and oxygen toxicity 
(26). Exogenous TNF (27, 28) and IL-1 (29) similarly pro- 
tect rodents against subsequent lethal endotoxemia, yet when 
these cytokines are produced in response to LPS they mediate 
toxicity. Therefore, although exogenous D factor is protec- 
tive, endogenous D factor produced during an inflammatory 
response, analogous to endogenous TNF and IL-1, may con- 
tribute to toxicity. 
We hypothesized D factor is produced as part of the host 
response to an immune system stimulus and participates in 
the network of eytokine interactions activated during acute 
injury and inflammation. To test this hypothesis we conducted 
experiments using endotoxemia in adult mice as a model of 
sepsis and investigated: (a) tissue D  factor gene expression 
before and after intraperitoneal administration of LPS;  (b) 
the effect of passive immunization against D  factor on sur- 
vival after a lethal dose of LPS; and (c) the effect of passive 
immunization against D factor on levels of circulating TNF, 
IL-1,  IL-6,  and IFN-3  ~ after LPS administration. 
Materials and Methods 
Animals.  Female  C57B1/6 mice weighing 19-21 g were group 
housed five to six per cage in the animal care facility of the Na- 
tional Institutes of Health (NIH; Bethesda, MD), with access to 
food and water ad libitum. All experiments were conducted in com- 
pliance with the guidelines of the Animal Care and Use Committee 
of the NIH. 
Reagents.  Recombinant murine D factor was a gift of Genen- 
tech, Inc. (South San Francisco, CA). Rabbit nonimmune IgG (IgG) 
was purchased from ICN Immunobiologicals (Costa Mesa, CA). 
Endotoxin (Escherichia coli LPS, serotype 0127:B8) was purchased 
from Sigma Chemical Co.  (St. Louis, MO). 
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with LPS (35 mg/kg body weight). Livers, lungs, and spleens were 
harvested from two mice at each of the time points indicated and 
snap  frozen  in  liquid  nitrogen.  Tissues were  then  pulverized, 
homogenized in guanidinium  thiocyanate buffer, and total RNA 
was isolated by phenol/chloroform  extraction. RNA was also iso- 
lated from cultured RAW 264.7 cells (American Type Culture Col- 
lection, Rockville, MD) before and 6 h after stimulation with LPS 
(1 /~g/ml). 
Reterse Transc@tase  (RT) PCR.  Primers  specifying  a 601-bp frag- 
ment of murine  D factor cDNA for amplification were synthe- 
sized (392 DNA/RNA  Synthesizer;  Applied  Biosystems, Inc., 
Foster City, CA) based on the published sequence of routine  D 
factor (GenBank no. M63419) and corresponded to sequences from 
exon  1  (sense primer:  5'-GGAGTCCAGCCCATAATGAAGG- 
TCTTGGC-3') and exon 3 (antisense primer:  5'-TGACTTGC- 
TTGTATGTCCCCAGAAGCTGG-3 '). 
Total RNA (0.5 #g) from each sample was reverse transcribed 
using  the antisense primer  (1.0/~M)  and the entire product  (10 
#1) amplified in a final volume of 50 #1 PCR buffer for 38 cycles 
(95~  for 40 s, 70~  for 30 s). A 30% portion  of the reaction 
products  (15/A) was analyzed by electrophoresis on an ethidium 
bromide-stained  1.5% agarose gel. Visualized bands were of ex- 
pected size (601 bp) and identity was confirmed by restriction en- 
donuclease digestion  with  MboI and SmaI (Bethesda Research 
Laboratories, Gaithersburg, MD). Reagents for RT-PCR were pur- 
chased from Perkin Elmer Cetus (GeneAmp  |  RNA PCR kit; Nor- 
walk,  CT). 
D Factor  Antibody.  Using a protocol that has been previously 
described (30), we generated polyclonal antibodies against murine 
D factor (DF Ab) by inoculating New Zealand White rabbits with 
recombinant murine D factor. Immune serum was collected at in- 
tervals after boosting and the IgG fraction was purified over a pro- 
tein G column (Clinetics Corp., La Jolla, CA). Endotoxin content 
of this preparation  was <0.1  ng/mg protein  (limulus amebocyte 
lysate assay; Whittaker Bioproducts, Walkersville, MD). DF Ab 
and IgG were brought to a final concentration in sterile saline and 
administered intraperitoneaUy. 
Western Blot.  Murine  cytokines  (25  ng each: D  factor  and 
TNF-cx [Genentech, Inc., South San Francisco, CA]; IL-lcz, II--13, 
and II~6 [Ik & D Systems, Minneapolis, MN]; IFN-v [Amgen Bi- 
ologicals, Thousand Oaks, CA]) and LPS were separated on a 14% 
polyacrylamide gel (Novex, San Diego, CA) under reducing con- 
ditions. Proteins were transferred to a nitrocellulose membrane and 
incubated with DF Ab (31.5/~g/ml final concentration), then with 
horseradish peroxidase-conjugated affinity-purified goat anti-rabbit 
IgG (Bio-Rad Laboratories, Richmond, CA), diluted 1:2,000. Blots 
were developed using an enhanced chemiluminescence procedure 
(Amersham Corp., Arlington  Heights, IL) and exposed to photo- 
graphic film for -3 rain. 
M1 Assay.  M1-T22 murine leukemia cells (gift of Genen- 
tech,  Inc.)  were  added  to  wells  of a  96-well  plate  (10  4 
cells/well) in 100/zl of culture medium (Eagle's MEM with 
10% heat-inactivated FCS, lx  t-glutamine,  lx  sodium pyru- 
vate, 2 x  nonessential amino acids, vitamins, penicillin, strep- 
tomycin, and gentamicin sulfate [Biofluids, Inc., Rockville, 
MD]). DF Ab was diluted in culture medium and 90 #1 was 
added to each well to give final concentrations of 0.01, 0.1, 
1.0, 10.0, and 50.0 ng/ml. After 15 rain, D factor was added 
in  10 #l of medium  to give final  concentrations  of 1.0  or 
10.0 ng/ml.  Control wells received equivalent  volumes of 
medium alone. Cells were incubated at 37~  5% CO2 for 
68 h, followed by the addition of 1 #Ci [3H]thymidine per 
well (NEN Research Products, DuPont Co., Boston, MA). 
After 4 h, cells were harvested with a cell harvester (1295-001; 
LKB Instruments,  Gaithersburg,  MD)  and  [3H]thymidine 
incorporation was measured on a beta plate liquid scintilla- 
tion counter  (1205;  LKB Instruments). 
Effect of  D Factor  Antibody on Survival after LPS.  Mice were 
treated with  1 mg of either DF Ab or IgG (reconstituted 
to  2  mg/ml  in  sterile  saline  and  0.5  ml  administered  in- 
traperitoneally) 6 h before, 30 min after, or I h after adminis- 
tration of LPS (reconstituted to 3.5 mg/ml in sterile saline 
and 35 mg/kg body weight administered intraperitoneally). 
Survival  was  recorded  at  regular  intervals,  and  statistical 
significance  was  assessed  by  the  Breslow  modification  of 
Kruskal-Wallis test. After 4 d, surviving animals were nor- 
mally active and appeared fully recovered. All mice were ear- 
tagged and randomized,  and reagents were administered in 
a blinded fashion. 
Effect of D Factor Antibody on Circulating Cytokine  Levels 
after LPS.  LPS was reconstituted to 0.2 mg/ml in sterile 
saline and given by intravenous tail vein injection (2 mg/kg 
body weight) 6 h after a l-rag intraperitoneal dose of either 
DF Ab or nonimmune IgG. Blood was collected from naive 
(time  =  0) and endotoxemic mice (1, 3, and 6 h after intra- 
venous LPS) by retroorbital puncture and allowed to clot at 
0-4~  Samples were centrifuged for 15 rain at 4~  and the 
supernatant (serum) was collected. Determinations ofcytokine 
levels were made by ELISA: murine (mu)TNF-o6 mulL-lo~, 
and mulFN-3~ (Genzyme, Boston, MA), and mulL-6 (En- 
dogen Inc.,  Boston,  MA). 
Results and Discussion 
Comparison of product yields from RT-PCR analyses of 
RNA  from resting  and  LPS-stimulated  RAW  264.7  ceils 
shows the ability of RT-PCR to detect D factor gene induc- 
tion (Fig.  1). Similar analysis of RNA isolated from tissues 
of naive and endotoxemic mice shows that D factor gene ex- 
pression was induced in both liver and spleen tissue within 
I h of intraperitoneal administration of LPS. D factor mRNA 
was detected in the lung tissue of naive mice, indicating some 
constitutive expression.  Consistent with the findings of others 
(1, 2), Northern blot analyses were insufficiently sensitive to 
detect D  factor mKNA in total RNA and mKNA prepara- 
tions derived from tissues (data not shown).  This suggests 
that  D  factor transcripts  were present  either in low abun- 
dance in all parenchymal cells, in only a small population of 
parenchymal cells, or in circulating cells trapped in the organ 
at  the time of death. 
Despite the ability to detect induction  of D  factor gene 
expression during endotoxemia, synthesis of the protein has 
been difficult to confirm. We have used both Western blot 
and ELISAs to detect LPS-induced D  factor production by 
RAW 264.7 cells in vitro (M.  I.  Block, K.  G. BiUingsley, 
and H. R. Alexander, unpublished observations). However, 
using these techniques, we have been unable to detect D factor 
in the serum of endotoxemic mice. The more sensitive but 
1086  D Factor Mediates Lethality of Endotoxin Figure  1.  Induction of D  factor gene expression during endotoxemia 
in mice. Comparison of product yields  shows  the ability of RT-PCR to 
detect D factor gene induction in RAW 264.7 cells exposed to LPS (top). 
Similar analysis of RNA isolated from naive (time =  0) and endotoxemic 
mice (time after LPS indicated) shows induction of gene expression in both 
the liver and spleen during endotoxemia; constitutive expression was de- 
tected in the lung. 
potentially less  specific bioassay  was used by Metcalf (31), 
who measured circulating D  factor in the same model and 
detected peak levels occurring 2 h after intravenous LPS. These 
findings suggest that circulating levels are either episodic or 
remain low during endotoxemia, and that D  factor may act 
primarily  at  the tissue level. 
The observation  that D  factor gene transcription  can be 
induced by administration  of LPS supports  the hypothesis 
that  D  factor plays an important role in the host response 
to an inflammatory stimulus. To better understand this role, 
antibodies  against murine D  factor (DF Ab) were generated 
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Figure  3.  Passive  immuniza- 
tion against D factor protects mice 
from the lethal effects of endotox- 
emia.  Kaplan-Meier  survival 
curves  for  endotoxemic  mice 
treated with either DF Ab or con- 
trol nonimmune rabbit IgG. (A) 
Treatment  with  either  DF  Ab 
(n =  11) or IgG (n  =  10) 6 h be- 
fore LPS; p <  0.001.  (B) DF Ab 
(n  =  11) orIgG(n  =  12)  was 
given  30  min  after  LPS;  p  = 
0.008.  Control mice treated after 
LPS  (/3) had  improved survival 
compared  with  control  mice 
treated before LPS (A), consistent 
with a resuscitative  benefit from 
the fluid bolus alone. (C) DF Ab 
(n  =  18) or IgG (n  =  18)  was 
given 1 h  after LPS; p  ~  0.09. 
in rabbits and characterized for use in vivo.  Sensitivity and 
specificity  were tested  by Western  blot  analyses (Fig.  2, A 
and B), which demonstrated  that DF Ab was capable of de- 
tecting as little as 10 ng of recombinant routine D factor (Fig. 
2 A), and did not bind to other inflammatory murine cytokines 
or LPS (Fig.  2 B).  The neutralizing ability of DF Ab was 
demonstrated by dose-dependent inhibition of the antiprolifer- 
ative effects of D factor on M1 cells (Fig. 2 C). In the absence 
of DF Ab, increasing doses of D factor promoted the differen- 
tiation of M1 cells and decreased [3H]thymidine incorpora- 
tion. Increased  concentrations of DF Ab progressively inhibited 
D factor-induced M1 cell differentiation and restored prolifer- 
ation to control levels. DF Ab alone had no detectable effect 
on M1  cell differentiation. 
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Figure  2.  Sensitivity,  specifi- 
city, and neutralizing ability  of  DF 
Ab. (A) Western blot of 10, 20, 
and 50 ng of recombinant murine 
D factor shows sensitivity of DF 
Ab.  (/3) Western blot  showing 
specific binding of DF Ab to D 
factor, but not to TNF-ol, IL-lc~, 
Ib13, 1I.-6, IFN-3", or LPS. Posi- 
tions of molecuhr weight markers 
are shown. (C) Proliferating M1 
cells  were  treated with  varying 
amounts of D  factor and DF Ab 
in the presence of [3H]thymidine. 
Increasing  factor  activity 
promoted differentiation and re- 
duced [3H]thymidine incorpora- 
tion. Neutralization of D  factor 
activity by DF Ab ~stored M1 cell 
proliferation to control levels. Passive immunization of mice with DF Ab protected them 
from the subsequent effects  of  lethal endotoxemia and identified 
an optimum antibody dose of 1 mg per mouse (data not 
shown). In subsequent studies, mortality among mice given 
DF Ab 6 h before (Fig. 3 A) and 2 h before (data not shown) 
intraperitoneal  LPS was significantly lower than mortality 
among control mice. Use of a different, affinity-purified  rabbit 
anti-murine D factor antibody (gift of Genentech) achieved 
similar results (data not shown). DF Ab also improved sur- 
vival when given 30 min after LPS (Fig. 3 B); this therapeutic 
effect is similar to that seen during endotoxemia with ad- 
ministration of the IL-1 receptor antagonist  (IL-lra) (32), 
an agent currently being evaluated in clinical trials for the 
treatment of septicemia. Although the survival difference  was 
not statistically significant when DF Ab was administered 
1 h after LPS (Fig. 3 C), multiple repeated experiments demon- 
strated a small but consistent improvement. These results in- 
dicate that D factor produced by the host in response to LPS 
is necessary for the lethal consequences of endotoxemia. 
Critical early mediators of systemic  toxidty during endotox- 
emia, such  as TNF and IL-1, are released  into the serum quickly 
and can reproduce the manifestations of endotoxic shock when 
administered alone or in combination. Administration of D 
factor has not been shown to reproduce the acute toxicity 
associated with these cytokines. Although D factor alone may 
not induce a fulminant inflammatory response, the improve- 
ment in survival with passive immunization against D factor 
suggests that D factor may be a necessary component in the 
network of cytokine interactions activated during endotox- 
emia. To assess the role olD factor in modulating the cytokine 
response to LPS, we measured circulating levels of TNF, IL-1, 
IL-6, and IFN-'y during endotoxemia in passively  immunized 
(DF Ab) and control (nonimmune IgG) mice after intrave- 
nous LPS (Fig. 4). In repeated experiments, no deaths were 
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Figure  4.  D  factor mediates cytokine appearance  in the serum of en- 
dotoxemic mice. Serum cytokine levels in mice pretreated with either DF 
Ab or IgG (mean +_ SE) are plotted vs. time after intravenous LPS; n >t 
5 for all groups. Horizontal dashed lines represent the minimum level de- 
tectable;  *p <0.05 by unpaired, two tailed Student's t test. 
seen among mice pretreated with DF Ab, whereas the mor- 
tality rate of control mice was consistently near 30% (data 
not shown).  In DF Ab-pretreated mice the initial peak in 
serum levels of TNF was unaffected, although the return to 
baseline was more rapid compared with controls (Fig. 4 A). 
In contrast,  pretreatment with DF Ab significantly attenu- 
ated the increase in circulating levels of IL-1 and IL-6 seen 
after LPS administration (Figs. 4, B and C, respectively).  Serum 
levels of IFN-3~ increased  later and were unaffected  by blocking 
D  factor activity (Fig. 4 D). These results indicate that D 
factor is an early mediator of cytokine release in response to 
LPS, necessary for IL-1 and IL-6, but not IFN-y, secretion. 
D factor does not appear to be necessary  for the initial produc- 
tion of TNF in response to LPS, but may be required either 
directly, or indirectly through modulation of IL-1 levels, for 
sustained TNF production. 
The hose response during sepsis involves complex interac- 
tions between endogenous protein and lipid mediators. TNF 
is recognized to be an essential component of this network 
because  inhibition of its activity improves survival  and decreases 
production of other mediators (IL-1 and IL-6) (33-35). The 
current studies show that D factor, like TNF, plays a critical 
early role in the pathophysiology of endotoxemia. Endotoxin 
administration induced D factor gene expression in vivo and 
inhibition of endogenous D factor activity improved survival 
and  decreased  IL-1  and  IL-6  production.  The  systemic 
manifestations of septic shock therefore may require both TNF 
and D factor activity. This effect is consistent with the hy- 
pothesis of Layton et al. (36), who recently identified a new 
tralizing soluble receptor (LIF binding protein [LBP]) present 
in the serum of normal mice and suggested that it acts to 
limit the systemic effects of locally produced D factor. LBP, 
analogous to DF Ab, may represent a natural inhibitory mech- 
anism to protect the host against systemic effects old factor 
produced during inflammation.  A human LBP has not yet 
been identified. 
The protection afforded rodents against radiation injury, 
oxygen toxicity, and endotoxemia by pretreatment with D 
factor seems inconsistent with the results of the present study. 
As noted, similar results have  been observed with both TNF 
and IL-1. Concerning D factor, changes in the level of cir- 
culating LBP may be important. Pregnant mice, which pro- 
duce greater amounts of D  factor than normal mice, have 
much higher levels of circulating LBP than do normal mice 
(36). This suggests that pretreatment of a mouse with D 
factor might induce production of LBP. The resulting  in- 
creased amount of circulating LBP could then neutralize sub- 
sequently produced D factor (e.g., in response to LPS) and 
thereby limit systemic toxicity. 
As an essential participant in the complex network of medi- 
ators activated during endotoxemia, D factor may also con- 
tribute to the pathophysiology  of other cytokine-mediated 
and inflammatory conditions,  such as arthritis,  aUograft re- 
jection, cancer cachexia, autoimmune disease, and the im- 
munotherapy of cancer. Although its role in these conditions 
remains to be determined, the ability to modulate endoge- 
nous production and activity old factor may have therapeutic 
application. 
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